<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Chronic Lymphocytic Leukemia (CLL)</title>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="../styles/main.css">
    <!-- Include MathJax -->
    <script>
    MathJax = {
        tex: {
            inlineMath: [['$', '$'], ['\(', '\)']],
            displayMath: [['$$', '$$'], ['\[', '\]']],
            processEscapes: true,
            processEnvironments: true,
            tags: 'ams' // Use AMS numbering of equations
        },
        svg: { fontCache: 'global' },
        options: {
            skipHtmlTags: ['script', 'noscript', 'style', 'textarea', 'pre']
        }
    };
    </script>
    <script src="https://polyfill.io/v3/polyfill.min.js?features=es6"></script>
    <script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
</head>
<body>
    <div class="container">
        <article class="document-section" role="main">
            <!-- Top Navigation -->
            <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="03-acute-lymphocytic-leukemia.html" class="nav-button"> 
                        <span class="nav-icon">←</span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 80%;"></div> 
                        </div>
                       <span class="progress-text">Lecture 4 of 5</span> 
                    </div>
                    <a href="05-chronic-myeloid-leukemia.html" class="nav-button"> 
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon">→</span>
                    </a>
                </div>
            </nav>

            <header class="section-header">
                <h1 class="section-title">Chronic Lymphocytic Leukemia (CLL)</h1>
                <div class="title-underline"></div>
            </header>

            <main class="section-content">
                <!-- START: background-pathophysiology -->
                <section id="background-pathophysiology" class="content-section" aria-labelledby="section-heading-1">
                    <h2 id="section-heading-1" class="section-heading">
                         <span class="heading-icon"> </span>
                        <span class="heading-text">Background and Pathophysiology</span>
                    </h2>
                    <div class="content-card">
                        <p>Chronic Lymphocytic Leukemia (CLL) is a monoclonal disorder characterized by a progressive accumulation of functionally incompetent lymphocytes. It is the most common form of leukemia found in adults, typically affecting those aged 50-70 years.</p>
                        <p>The cells of origin in the majority of patients (75%) are clonal B cells arrested in their differentiation pathway. Morphologically, these cells resemble mature lymphocytes. These B-CLL lymphocytes typically express B-cell surface antigens (CD19, CD20, CD21, CD24) and also CD5, which is more commonly found on T cells.</p>
                        <p>The proto-oncogene <strong>bcl2</strong> is known to be overexpressed in B-CLL. Bcl2 is a suppressor of apoptosis (programmed cell death), which results in a long life for the involved cells.</p>
                        <p>An abnormal karyotype is observed in most patients. Common abnormalities include:</p>
                        <ul class="enhanced-list">
                            <li class="list-item"><span class="item-icon">•</span><span class="item-text"><strong>Deletion of 13q:</strong> Occurs in over 50% of patients and is associated with a relatively benign disease.</span></li>
                            <li class="list-item"><span class="item-icon">•</span><span class="item-text"><strong>Trisomy 12:</strong> Observed in 15% of patients, associated with atypical morphology and progressive disease.</span></li>
                            <li class="list-item"><span class="item-icon">•</span><span class="item-text"><strong>Deletions of 11q22-q23:</strong> Found in 19% of patients, associated with extensive lymph node involvement and aggressive disease.</span></li>
                        </ul>
                    </div>
                </section>
                <!-- END: background-pathophysiology -->

                <!-- START: clinical-presentation -->
                <section id="clinical-presentation" class="content-section" aria-labelledby="section-heading-2">
                    <h2 id="section-heading-2" class="section-heading">
                         <span class="heading-icon"> </span>
                         <span class="heading-text">Clinical Presentation</span>
                    </h2>
                    <div class="content-card">
                        <h3 class="subsection-heading">History</h3>
                        <p>The onset is insidious, and the disorder is often discovered incidentally. Common symptoms include:</p>
                        <ul class="enhanced-list">
                            <li class="list-item"><span class="item-icon">✓</span><span class="item-text">Predisposition to repeated infections (e.g., pneumonia, herpes simplex).</span></li>
                            <li class="list-item"><span class="item-icon">✓</span><span class="item-text">Enlarged lymph nodes.</span></li>
                            <li class="list-item"><span class="item-icon">✓</span><span class="item-text">Early satiety and/or abdominal discomfort from an enlarged spleen.</span></li>
                            <li class="list-item"><span class="item-icon">✓</span><span class="item-text">Mucocutaneous bleeding and/or petechiae due to thrombocytopenia.</span></li>
                            <li class="list-item"><span class="item-icon">✓</span><span class="item-text">Tiredness and fatigue from anemia.</span></li>
                            <li class="list-item"><span class="item-icon">✓</span><span class="item-text">Pruritic vesicular skin lesions.</span></li>
                        </ul>
                        <h3 class="subsection-heading">Physical Examination</h3>
                         <ul class="enhanced-list">
                            <li class="list-item"><span class="item-icon">-</span><span class="item-text">Localized or generalized lymphadenopathy.</span></li>
                            <li class="list-item"><span class="item-icon">-</span><span class="item-text">Splenomegaly (30-40% of cases).</span></li>
                            <li class="list-item"><span class="item-icon">-</span><span class="item-text">Hepatomegaly (20% of cases).</span></li>
                            <li class="list-item"><span class="item-icon">-</span><span class="item-text">Petechiae and Pallor.</span></li>
                        </ul>
                    </div>
                </section>
                <!-- END: clinical-presentation -->

                <!-- START: staging -->
                <section id="staging" class="content-section" aria-labelledby="section-heading-3">
                    <h2 id="section-heading-3" class="section-heading">
                         <span class="heading-icon"> </span>
                         <span class="heading-text">Staging Systems</span>
                    </h2>
                    <div class="content-card">
                        <p>Two main staging systems are used:</p>
                        <h3 class="subsection-heading">Rai-Sawitsky Staging System (5 Stages)</h3>
                        <ul>
                            <li><strong>Stage 0:</strong> Lymphocytosis only. Survival > 120 months.</li>
                            <li><strong>Stage I:</strong> Lymphocytosis + adenopathy. Survival ~95 months.</li>
                            <li><strong>Stage II:</strong> Lymphocytosis + splenomegaly/hepatomegaly. Survival ~72 months.</li>
                            <li><strong>Stage III:</strong> Lymphocytosis + anemia (Hb < 10 g). Survival ~30 months.</li>
                            <li><strong>Stage IV:</strong> Lymphocytosis + thrombocytopenia (platelets < 100,000). Survival ~30 months.</li>
                        </ul>
                        <h3 class="subsection-heading">Binet Staging System (3 Stages)</h3>
                        <ul>
                            <li><strong>Stage A:</strong> Hemoglobin ≥ 100 g/L, platelets ≥ 100x10<sup>-9</sup>, and < 3 lymph node areas involved. Survival > 120 months.</li>
                            <li><strong>Stage B:</strong> Same blood counts as A, but with ≥ 3 lymph node areas involved. Survival ~61 months.</li>
                            <li><strong>Stage C:</strong> Hemoglobin < 100 g/L or platelets < 100x10<sup>-9</sup>. Survival ~32 months.</li>
                        </ul>
                    </div>
                </section>
                <!-- END: staging -->
                
                <!-- START: investigations -->
                <section id="investigations" class="content-section" aria-labelledby="section-heading-4">
                    <h2 id="section-heading-4" class="section-heading">
                         <span class="heading-icon"> </span>
                         <span class="heading-text">Investigations</span>
                    </h2>
                    <div class="content-card">
                         <ul class="enhanced-list">
                            <li class="list-item"><span class="item-icon">1.</span><span class="item-text"><strong>CBC with differential:</strong> Shows absolute lymphocytosis (> 5000 lymphocytes/mL), normocytic normochromic anemia, and thrombocytopenia. The WBC count can be elevated to 20,000-100,000/mm³.</span></li>
                            <li class="list-item"><span class="item-icon">2.</span><span class="item-text"><strong>Peripheral Blood Film (PBF):</strong> Confirms lymphocytosis and shows the presence of "smudge cells," which are artifacts from damaged lymphocytes during slide preparation.</span></li>
                            <li class="list-item"><span class="item-icon">3.</span><span class="item-text"><strong>Flow Cytometry:</strong> The most valuable test. It confirms circulating clonal B-lymphocytes expressing CD5, CD19, CD20(dim), and CD23.</span></li>
                            <li class="list-item"><span class="item-icon">4.</span><span class="item-text"><strong>Bone Marrow Aspiration and Biopsy:</strong> Shows increased mature lymphocytes (up to 40% vs normal <5%) and decreased myeloid, erythroid, and megakaryocytic cells. Blast transformation may occur (Richter syndrome).</span></li>
                            <li class="list-item"><span class="item-icon">5.</span><span class="item-text"><strong>Imaging Studies:</strong> Liver/spleen scan or CT may be used to demonstrate organomegaly or assess for organ compression by enlarged lymph nodes.</span></li>
                        </ul>
                    </div>
                </section>
                <!-- END: investigations -->
                
                <!-- START: management -->
                <section id="management" class="content-section" aria-labelledby="section-heading-5">
                    <h2 id="section-heading-5" class="section-heading">
                         <span class="heading-icon"> </span>
                         <span class="heading-text">Management</span>
                    </h2>
                    <div class="content-card">
                         <p>Patients at stable, early stages (Rai 0, I, II) may only require periodic follow-up. Chemotherapy is initiated for patients with:</p>
                         <ul class="enhanced-list">
                            <li class="list-item"><span class="item-icon">•</span><span class="item-text">Weight loss > 10%</span></li>
                            <li class="list-item"><span class="item-icon">•</span><span class="item-text">Extreme fatigue</span></li>
                            <li class="list-item"><span class="item-icon">•</span><span class="item-text">Fever or night sweats related to leukemia</span></li>
                            <li class="list-item"><span class="item-icon">•</span><span class="item-text">Progressive marrow failure</span></li>
                            <li class="list-item"><span class="item-icon">•</span><span class="item-text">Autoimmune anemia or thrombocytopenia not responding to prednisone</span></li>
                            <li class="list-item"><span class="item-icon">•</span><span class="item-text">Progressive splenomegaly or massive lymphadenopathy</span></li>
                             <li class="list-item"><span class="item-icon">•</span><span class="item-text">Progressive lymphocytosis (doubling time < 6 months)</span></li>
                        </ul>
                        <h3 class="subsection-heading">Treatment Options</h3>
                        <ol>
                            <li><strong>Prednisolone:</strong> Useful for autoimmune manifestations.</li>
                            <li><strong>Nucleoside Analogs:</strong> Fludarabine, Cladribine, Pentostatin. Fludarabine has high response rates (80%).</li>
                            <li><strong>Chlorambucil and Prednisone:</strong> An older combination with response rates of 38-47%.</li>
                            <li><strong>Monoclonal Antibodies:</strong> Rituximab (Rituxan) is an example.</li>
                        </ol>
                        <p>Management also involves antibiotics for infections.</p>
                    </div>
                </section>
                <!-- END: management -->
            </main>

            <!-- Bottom Navigation -->
             <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="03-acute-lymphocytic-leukemia.html" class="nav-button">
                        <span class="nav-icon">←</span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 80%;"></div>
                        </div>
                       <span class="progress-text">Lecture 4 of 5</span>
                    </div>
                    <a href="05-chronic-myeloid-leukemia.html" class="nav-button">
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon">→</span>
                    </a>
                </div>
            </nav>
        </article>
    </div>
    <script src="../js/navigation.js"></script>
</body>
</html>